Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xeris Biopharma Holdings (XERS) Tax Provisions: 2022-2024

Historic Tax Provisions for Xeris Biopharma Holdings (XERS) over the last 3 years, with Sep 2024 value amounting to -$3.3 million.

  • Xeris Biopharma Holdings' Tax Provisions fell 883.43% to -$3.3 million in Q3 2024 from the same period last year, while for Sep 2024 it was -$2.5 million, marking a year-over-year decrease of 48.17%. This contributed to the annual value of -$2.3 million for FY2024, which is 81.59% down from last year.
  • Xeris Biopharma Holdings' Tax Provisions amounted to -$3.3 million in Q3 2024, which was down 543.79% from $749,000 recorded in Q2 2024.
  • Over the past 5 years, Xeris Biopharma Holdings' Tax Provisions peaked at $749,000 during Q2 2024, and registered a low of -$3.3 million during Q3 2024.
  • For the 3-year period, Xeris Biopharma Holdings' Tax Provisions averaged around -$494,100, with its median value being -$338,500 (2022).
  • Over the last 5 years, Xeris Biopharma Holdings' Tax Provisions had its largest YoY gain of 210.96% in 2024, and its largest YoY loss of 883.43% in 2024.
  • Xeris Biopharma Holdings' Tax Provisions (Quarterly) stood at -$338,000 in 2022, then spiked by 30.18% to -$236,000 in 2023, then slumped by 883.43% to -$3.3 million in 2024.
  • Its last three reported values are -$3.3 million in Q3 2024, $749,000 for Q2 2024, and $307,000 during Q1 2024.